$48.41
1.19% day before yesterday
NYSE, Jun 06, 10:10 pm CET
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Bristol-Myers Squibb Stock News

Positive
Seeking Alpha
one day ago
Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327, targeting large cancer markets, with a deal structure that limits BMY's downside risk. BMY's established cash flows, low payout ratio, and current low valuation make it a safer, income-generating...
Positive
24/7 Wall Street
4 days ago
While reaching retirement age can be both a blessing and a curse, relying on the U.S.
Positive
CNBC
4 days ago
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Positive
Invezz
5 days ago
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth announced the said partnership at ASCO, the world's largest cancer conference in Chicago.
Positive
Market Watch
5 days ago
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
Positive
WSJ
6 days ago
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Positive
Reuters
6 days ago
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 billion in value for BioNTech.
Neutral
Business Wire
6 days ago
MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today